Dynamics Within Industry-Academia Partnerships Changing - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "CNS Drug News Issue 371" report to their offering.

The favourable terms for academia in the deal highlight a shift in dynamics in industry-academia partnership. As more big pharma companies seek to leverage open innovation to drive lower cost, faster and more flexible R&D, competition for top institutions will increase. We expect a move away from academia being seen as just a provider of early research for the industry, towards more equally weighted partnerships.

Key Topics Covered:

1. Neurodegenerative Disorders

  1. Parkinson's Disease
  2. Ntcell Continues To Stop PD Progression One Year After Implant
  3. Amarantus Secures Chinese Patent Covering Use Of MANF For PD

2. Antidepressants

  • Alkermes Trial Failures Raise MDD Development Doubts
  • Breakthrough Designation For Rapastinel Enhances Competitive Position

3. Psychotic Disorders

  • Neos' Adzenys XR-ODT FDA-Approved To Treat ADHD

4. Analgesics/Anaesthetics

  • Trevena Initiated Oliceridine Phase III Programme In Acute Pain
  • Dr Reddy's Gains FDA Sumatriptan Approval
  • First Patient Dosed In Meloxicam Phase III Trial
  • FDA Approves Onzetra Xsail To Treat Acute Migraine In Adults
  • Braeburn/Knight Sign Canadian Probuphine Licensing Deal

5. Therapies to Treat Substance Dependence

  • Akorn Launches Buprenorphine/Naloxone Tablets And Tobramycin Injection

6. Anti-Epileptics

  • Zogenix' ZX008 Gains FDA Fast Track Designation For Dravet Syndrome
  • Mylan Launches Felbamate Tablets
  • Briviact Approval Maintains UCB's Epilepsy Focus
  • Aprecia Raises Funds To Advance Commercialisation Of 3D Printed Spritam

7. Eating Disorders

  • Patient Risk Profile Key For Beloranib Success

8. General Development News

  • Need For CNS Therapies Continues To Attract Research Agreements
  • FDA Approves Botox For Lower Limb Spasticity In Adults

9. Corporate Activity

  • vasopharm Raises Funds For Phase III Study Of VAS203 In TBI
  • J&J Focusing On Long-Term Neuroscience Performance
  • Diversification Key To Overcoming Tecfidera Reliance

For more information visit http://www.researchandmarkets.com/research/f5wp9t/cns_drug_news

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs